 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 4
Subject Collection: Medicine
Pages: 526-530
DOI: 10.5272/jimab.2014204.526
Published online: 29 September 2014
J of IMAB 2014 Jul-Sep;20(4):526-530
CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS.
Liana Gercheva 
, Antonina Zhelyazkova, Ilina Micheva, Neli Zgurova, Maria Tzaneva, Georgi Balatzenko.
Clinic of Hematology, Medical University, Varna, University Hospital "St. Marina", Varna, Bulgaria.
ABSTRACT:
JAK2V617F mutation is a well-recognized feature in most Ph-negative myeloproliferative neoplasms (MPNs). An activated bone marrow (BM) angiogenesis has been established in these disorders as well. Consequently, the rational question is to ascertain a possible relation among JAK2 mutation, morphological features and angiogenesis in MPNs bone marrow.
Aim: To assess bone marrow microvessel density (MVD), bone marrow cellularity and fibrosis in newly diagnosed patients with BCR-ABL-negative MPNs, and define a correlation between the degree of angiogenesis in the bone marrow and JAK2V617F mutant allele burden.
Methods: JAK2 mutational burden was determined by RT-PCR, BM angiogenesis was defined by MVDassessment using anti-CD34 for BM endothelium staining. The BM fibrosis was evaluated according to the Hanover system. The statistical analysis was performed with SPSS 17.0 software. 52 patients with newly diagnosed MPN were included in the study.
Results: The distribution of the mutational burden was as follows: 26 patients with polycythaemia vera (PV), 16 patients with primary myelofibrosis (PMF) and 10 patients with essential thrombocythaemia (ET). In patients with PV the homozygosity was found prevalent in frequency whereas in PMF and ET the heterozygous variants were dominant. In all patients a significant positive correlations between JAK2V617F and BM MVD (r=0.306, p<0.002) and between MVD and fibrosis, (r=0.523, p<0.0001), was found.JAK2 correlated positively but borderline with fibrosis. The MVD and JAK2 burden were found in significant negative correlation with the BM cellularity (r=-0.405; p<0.002 and r=-0.431, p<0.0001, resp.).
Conclusions: The significant correlation between JAK2V617F, BM angiogenic activity and the fibrosis marks out the JAK2 allele burden as a feasible parameter with prognostic significance for evolution and progression of MPN.
Key words: JAK2V617F mutation, angiogenesis, myeloproliferative neoplasm, polycythaemiavera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF),
- Download FULL TEXT /PDF 887 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Gercheva L, Zhelyazkova A, Micheva I, Zgurova N, Tzaneva M, Balatzenko G. CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS. J of IMAB. 2014 Jul-Sep;20(4):526-530. http://dx.doi.org/10.5272/jimab.2014204.526.
Correspondence to: Assoc. Prof. Liana T. Gercheva, MD, PhD, Head of Clinic of Hematology, University Hospital St. Marina - Varna; 1, Hristo Smirnenski str, 9002 Varna, Bulgaria; E-mail: lianagercheva@gmail.com
REFERENCES:
1. Mertens C, Darnell JE Jr. SnapShot: JAK-STAT signaling. Cell. 2007 Nov 2;131(3):612-616. [PubMed] [CrossRef]
2. Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, et al. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. APMIS. 2011 Aug;119(8):498-504. [PubMed] [CrossRef]
3. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538. [PubMed] [CrossRef]
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptor. Nat Med. 2003 Jun;9(6):669-676. [PubMed] [CrossRef]
5. Steurer M, Zoller H, Augustin F, Fong D, Heiss S, Strasser-Weippl K, et al. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol. 2007 Jul;38(7):1057-1064. [PubMed] [CrossRef]
6. Zhelyazkova AG, Gercheva LT, Kolova P, Tonchev AB. Analysis of bone marrow pathology, angiogenesis and clinical parameters in patients with Philadelphia – negative myeloproloferative disorders. 14-th Congress of EHA, Berlin, June 4 – 7, 2009, abst. 1254, Poster session. [Haematologica. 2009 June 1;94(supplement 2)]
7. Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, et al. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. Am J Clin Pathol. 2007 Dec;128(6):966-973. [PubMed] [CrossRef]
8. Boveri E, Passamonti F, Rumi E, Pietra D, ;Elena C, rcaini L, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 117 patients with clinicopathological and molecular correlations. Br J Haematol. 2008 Jan;140(2):162-168. [PubMed] [CrossRef]
9. Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, et al. Angiogenesis and vascular endothelial growth factor/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2V617F mutational status. Br J Haematol. 2009 Jul;146(2):150-157. [PubMed] [CrossRef]
10. Silva WA Jr, Bonatto SL, Holanda AJ, Ribeiro-Dos-Santos AK, Paixão BM, Goldman GH, et al. Mitochondrial genome diversity of Native Americans supports a single early entry of founder populations into America. Am J Hum Genet. 2002 Jul;71(1):187-92. [PubMed]
11. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999 Dec;13(12):1901-28. [PubMed]
12. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19-25;365(9464):1054-61. [PubMed]
13. Verstovsek S, Odenike O, Scott B, Estrov Z, Cortes J, Thomas D, et al. (2009) Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis Blood 114: Abstract 3905.
14. Disease Control Priorities in Developing Countries, 2nd edition. Disease Control Priorities Project. Edited by Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P. Washington (DC): World Bank; 2006. [NBK]
15. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakasaki T, et al. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncol. 2007 Sep;43(8):785-790. [Pubmed] [CrossRef]
16. Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, et al. JAK2/ STAT3 signaling pathway activation mediates tumor angiogenesis by up-regulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 2011 Sep;73(3):366-374. [PubMed] [CrossRef]
17. Huang W, Yu LF, Zhong J, Wu W, Zhu JY, Jiang FX, et al. Stat3 is involved in angiotensin-II induced expression of MMP2 in gastric cancer cells. Dig Dis Sci. 2009 Oct;54(10):2056-2062. [PubMed] [CrossRef]
18. Tretinski J, Wierzbowska A, Krawczynska A, Sakowicz A, Pietrucha T, Smolewski P, et al. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol. 2010 Jun;91(5):792-798. [PubMed] [CrossRef]
19. Zhelyazkova A, Gercheva L, Ivanova L, Tzvetkov N, Antonov A. Elevated plasmatic concentrations of Vascular Endothelial Growth Factor and Hepatocyte Growth Factor in patients with chronic myeloproliferative disorders. Clinical and Transfusion Haematology; 2003; 39(3-4):24-31. [in Bulgarian]
20. Brecquevill M, Rey I, Devillier R, Guille A, Gillet R, Adélaide J, et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica. 2014 Jan;99(1):37-45. [PubMed] [CrossRef]
21. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013, Dec 19;369(25):2391-405. [PubMed] [CrossRef].
Received: 17 June 2014
Published online: 29 September 2014